Compass Biotechnologies Inc. Announces Acquisition of efsAUDIO Inc.
February 05 2016 - 8:30AM
Access Wire
SALT LAKE CITY, UT / ACCESSWIRE / February 5, 2016
/ Compass Biotechnologies Inc. (OTC PINK: COBI)
(PINKSHEETS: COBI) (Compass) is pleased to announce the previously
mentioned acquisition target is efsAUDIO Inc., manufacturer of the
Motion Sound product line. Since 1994, Motion Sound products have
been developed and manufactured with the focus on innovation,
quality, reliability and tone. Motion Sound amplifiers are
recognized as an industry standard through their quality and
innovation in proprietary rotary speaker technology and stereo
amplification for organs, pianos and synthesizers. Motion Sound
keyboard and guitar amplifiers are used and endorsed by well-known
artists throughout the world. To view a list of artists, please
visit the Motion Sound web site at www.msamps.com.
The completion of the acquisition of efsAUDIO is expected late
next week, which will result in efsAUDIO becoming a subsidiary of
Compass. The Company will effect a name change to reflect its new
business direction after the acquisition is completed.
It has come to our attention that several recent inquiries have
gone unanswered due to technical difficulties with our email system
and investor phone line. We would like to apologize for any absence
in communications, and these issues have been rectified.
Compass Biotechnologies Inc., (OTC PINKSHEETS: COBI.PK)
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, ability to obtain financing and
regulatory and shareholder approval for anticipated actions.
Contact Person:
Rick Shykora
At: compassbiotechnologies@gmail.com
(972) 535-8931
SOURCE: Compass Biotechnologies Inc.